Search research articles
Contact Us
Filters
Showing results (101-110 of 155) with videos related to
Page
of 16
Sort By:
Cancer Research
|
June 19, 2007
Regression of experimental medulloblastoma following transfer of HER2-specific T cells
Nabil Ahmed, Maheshika Ratnayake, Barbara Savoldo, et al.
Blood
|
March 17, 2011
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor
Greta Maria Paola Giordano Attianese, Virna Marin, Valentina Hoyos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2018
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Gunilla Enblad, Hannah Karlsson, Gustav Gammelgård, et al.
Cellular & Molecular Immunology
|
June 27, 2024
4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20
Zhangqi Dou, Thomas Raphael Bonacci, Peishun Shou, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 5, 2009
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7
Juan F Vera, Valentina Hoyos, Barbara Savoldo, et al.
Cancer Immunology Research
|
September 14, 2019
Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes
Christof C Smith, Shengjie Chai, Amber R Washington, et al.
Nature Communications
|
June 18, 2024
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Elisa Landoni, Mark G Woodcock, Gabriel Barragan, et al.
International Journal of Cancer
|
September 4, 2019
In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab
Sara Caratelli, Roberto Arriga, Tommaso Sconocchia, et al.
Nature Communications
|
January 3, 2024
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Elisa Landoni, Mark G Woodcock, Gabriel Barragan, et al.
Journal for Immunotherapy of Cancer
|
August 1, 2023
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
Nicholas P Tschernia, Hillary Heiling, Allison M Deal, et al.
Page
of 16
Search research articles
Search
Showing results (101-110 of 155) with videos related to
Sort By:
Page
of 16
Cancer Research
|
June 19, 2007
Regression of experimental medulloblastoma following transfer of HER2-specific T cells
Nabil Ahmed, Maheshika Ratnayake, Barbara Savoldo, et al.
Blood
|
March 17, 2011
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor
Greta Maria Paola Giordano Attianese, Virna Marin, Valentina Hoyos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2018
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Gunilla Enblad, Hannah Karlsson, Gustav Gammelgård, et al.
Cellular & Molecular Immunology
|
June 27, 2024
4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20
Zhangqi Dou, Thomas Raphael Bonacci, Peishun Shou, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 5, 2009
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7
Juan F Vera, Valentina Hoyos, Barbara Savoldo, et al.
Cancer Immunology Research
|
September 14, 2019
Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes
Christof C Smith, Shengjie Chai, Amber R Washington, et al.
Nature Communications
|
June 18, 2024
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Elisa Landoni, Mark G Woodcock, Gabriel Barragan, et al.
International Journal of Cancer
|
September 4, 2019
In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab
Sara Caratelli, Roberto Arriga, Tommaso Sconocchia, et al.
Nature Communications
|
January 3, 2024
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Elisa Landoni, Mark G Woodcock, Gabriel Barragan, et al.
Journal for Immunotherapy of Cancer
|
August 1, 2023
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
Nicholas P Tschernia, Hillary Heiling, Allison M Deal, et al.
Page
of 16